Role of chymase-dependent angiotensin II formation in monocrotaline-induced pulmonary hypertensive rats

Pediatric Research

Volumn 60, Issue 1, 2006, Pages 77-82

  Kishi, Kanta ^a   Jin, Denan ^a   Takai, Shinji ^a   Muramatsu, Michiko ^a   Katayama, Hiroshi ^a   Tamai, Hiroshi ^a   Miyazaki, Mizuo ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CHYMASE; MONOCROTALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOLE; ARTICLE; CHEMICAL ANALYSIS; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; HEART RIGHT VENTRICLE HYPERTROPHY; HEMODYNAMICS; LUNG ARTERY PRESSURE; MALE; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; STATISTICAL SIGNIFICANCE;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BLOOD PRESSURE; CELL PROLIFERATION; CHYMASES; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; MALE; MONOCROTALINE; PEPTIDYL-DIPEPTIDASE A; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANGIOTENSIN; RNA, MESSENGER; SERINE ENDOPEPTIDASES; TETRAZOLES; TUNICA MEDIA;

EID: 33748041146     PISSN: 00313998     EISSN: None     Source Type: Journal    
DOI: 10.1203/01.pdr.0000219431.45075.d9     Document Type: Article

References (29)

1. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A 1990 Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 265:22348-22357
2. Takai S, Shiota N, Sakaguchi M, Muraguchi H, Matsumura E, Miyazaki M 1997 Characterization of chymase from human vascular tissues. Clin Chim Acta 265:13-20
3. Okunishi H, Oka Y, Shiota N, Kawamoto T, Song K, Miyazaki M 1993 Marked species-difference in the vascular angiotensin II-forming pathways: humans versus rodents. Jpn J Pharmacol 62:207-210
4. Takai S, Jin D, Muramatsu M, Miyazaki M 2004 Chymase as a novel target for the prevention of vascular diseases. Trends Pharmacol Sci 25:518-522
5. Murakami M, Karnik SS, Husain A 1995 Human prochymase activation. A novel role for heparin in zymogen processing. J Biol Chem 270:2218-2223
6. Wintroub BU, Schechter NB, Lazarus GS, Kaempfer CE, Schwartz LB 1984 Angiotensin I conversion by human and rat chymotryptic proteinases. J Invest Dermatol 83:336-339
7. Guo C, Ju H, Leung D, Massaeli H, Shi M, Rabinovitch M 2001 A novel vascular smooth muscle chymase is upregulated in hypertensive rats. J Clin Invest 107:703-715
8. Ju H, Gros R, You X, Tsang S, Husain M, Rabinovitch M 2001 Conditional and targeted overexpression of vascular chymase causes hypertension in transgenic mice. Proc Natl Acad Sci U S A 98:7469-7474
9. Takai S, Miyazaki M 2003 Application of a chymase inhibitor, NK3201, for prevention of vascular proliferation. Cardiovasc Drug Rev 21:185-198
10. Kay JM, Keane PM, Suyama KL, Gauthier D 1982 Angiotensin converting enzyme activity and evolution of pulmonary vascular disease in rats with monocrotaline pulmonary hypertension. Thorax 37:88-96
11. Jin D, Takai S, Yamada M, Sakaguchi M, Kamoshita K, Ishida K, Sukenaga Y, Miyazaki M 2003 Impact of chymase inhibitor on cardiac function and survival after myocardial infarction. Cardiovasc Res 60:413-420
12. Jones JE, Mendes L, Rudd MA, Russo G, Loscalzo J, Zhang YY 2002 Serial noninvasive assessment of progressive pulmonary hypertension in a rat model. Am J Physiol Heart Circ Physiol 283:H364-H371
13. Tei C, Dujardin KS, Hodge DO, Bailey KR, McGoon MD, Tajik AJ, Seward SB 1996 Doppler echocardiographic index for assessment of global right ventricular function. J Am Soc Echocardiogr 9:838-847
14. McMurtry MS, Bonnet S, Wu X, Dyck JR, Haromy A, Hashimoto K, Michelakis ED 2004 Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res 95:830-840
15. Kirimura K, Takai S, Jin D, Muramatsu M, Kishi K, Yoshikawa K, Nakabayashi M, Mino Y, Kimura I, Miyazaki M 2005 Role of chymase-dependent angiotensin II formation in regulating blood pressure in spontaneously hypertensive rats. Hypertens Res 28:457-464
16. Muramatsu M, Katada J, Hayashi I, Majima M 2000 Chymase as a proangiogenic factor. A possible involvement of chymase-angiotensin-dependent pathway in the hamster sponge angiogenesis model. J Biol Chem 275:5545-5552
17. Lam SY, Leung PS 2003 Chronic hypoxia activates a local angiotensin-generating system in rat carotid body. Mol Cell Endocrinol 203:147-153
18. Takai S, Kirimura K, Jin D, Muramatsu M, Yoshikawa K, Mino Y, Miyazaki M 2005 Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling. Hypertens Res 28:593-600
19. Jones JE, Walker JL, Song Y, Weiss N, Cardoso WV, Tuder RM, Loscalzo J, Zhang YY 2004 Effect of 5-lipoxygenase on the development of pulmonary hypertension in rats. Am J Physiol Heart Circ Physiol 286:H1775-H1784
20. Mitani Y, Ueda M, Maruyama K, Shimpo H, Kojima A, Matsumura M, Aoki K, Sakurai M 1999 Mast cell chymase in pulmonary hypertension. Thorax 54:88-90
21. Haworth SG 1987 Pulmonary vascular disease in ventricular septal defect: structural and functional correlations in lung biopsies from 85 patients, with outcome of intracardiac repair. J Pathol 152:157-168
22. Hamada H, Terai M, Kimura H, Hirano K, Oana S, Niimi H 1999 Increased expression of mast cell chymase in the lungs of patients with congenital heart disease associated with early pulmonary vascular disease. Am J Respir Crit Care Med 160:1303-1308
23. Urata H, Boehm KD, Philip A, Kinoshita A, Gabrovsek J, Bumpus FM, Husain A 1993 Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 91:1269-1281
24. Huang XR, Chen WY, Truong LD, Lan HY 2003 Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 14:1738-1747
25. Molteni A, Ward WF, Ts'ao CH, Hinz JM 1989 Monocrotaline-induced cardiopulmonary injury in rats. Modification by the neutrophil elastase inhibitor SC39026. Biochem Pharmacol 38:2411-2419
26. Okada K, Bernstein ML, Zhang W, Schuster DP, Botney MD 1998 Angiotensin-converting enzyme inhibition delays pulmonary vascular neointimal formation. Am J Respir Crit Care Med 158:939-950
27. Kanno S, Wu YJ, Lee PC, Billiar TR, Ho C 2001 Angiotensin-converting enzyme inhibitor preserves p21 and endothelial nitric oxide synthase expression in monocrotaline-induced pulmonary arterial hypertension in rats. Circulation 104:945-950
28. Cassis LA, Rippetoe PE, Soltis EE, Painter DJ, Fitz R, Gillespie MN 1992 Angiotensin II and monocrotaline-induced pulmonary hypertension: effect of losartan (DuP 753), a nonpeptide angiotensin type 1 receptor antagonist. J Pharmacol Exp Ther 262:1168-1172
29. Dalla Libera L, Ravara B, Angelini A, Rossini K, Sandri M, Thiene G, Battista Ambrosio G, Vescovo G 2001 Beneficial effects on skeletal muscle of the angiotensin II type 1 receptor blocker irbesartan in experimental heart failure. Circulation 103:2195-2200